Healthcare Industry News: Lannett
News Release - June 13, 2016
Lannett Receives FDA Approval For Neomycin Sulfate Tablets USP, 500 mg
PHILADELPHIA, June 13, 2016 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (LCI) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Neomycin Sulfate Tablets USP, 500 mg, the therapeutic equivalent to the reference listed drug, Neomycin Sulfate Tablets USP, 500 mg, of Teva Pharmaceuticals USA, Inc. According to IMS, total U.S. sales in 2015 of Neomycin Sulfate Tablets USP, 500 mg, at Average Wholesale Price (AWP) were approximately $3 million."The approval for Neomycin Sulfate Tablets expands our portfolio of anti-infective and antibiotic products and represents our fifth approval in 2016," said Arthur Bedrosian, chief executive officer of Lannett. "We expect to commence marketing the product in the next several months, adding to our positive momentum as we enter the coming fiscal year."
About Lannett Company, Inc.
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.Lannett.com.
This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statement, including, but not limited to, successfully commercializing Neomycin Sulfate Tablets USP, 500 mg, whether expressed or implied, is subject to market and other conditions, and subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the risk factors discussed in the Company's Form 10-K and other documents filed with the SEC from time to time, including the prospectus supplement related to the proposed offering to be filed with the SEC. These forward-looking statements represent the Company's judgment as of the date of this news release. The Company disclaims any intent or obligation to update these forward-looking statements.
Source: Lannett Company
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
